



Advaxis to Present Corporate Overview at the Benzinga Biotech Small Cap Conference

March 23, 2021

PRINCETON, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- **Advaxis, Inc. (Nasdaq: ADXS)**, a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will participate in the Benzinga *Biotech Small Cap Conference to be held March 24-25, 2021*. Mr. Berlin will present on March 24th, 2021 at 2:30 pm ET.

Investors can view the presentation and request a 1x1 meeting once they register for the conference [here](#).

Tune in to the YouTube link on Day 1 Track 1 at 2:30 pm ET for the presentation: <https://www.youtube.com/watch?v=BOoOknbYO2c>

About Advaxis, Inc.

Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated *Listeria monocytogenes* (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.

To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.

Investor Contact

Tim McCarthy
LifeSci Advisors, LLC
Tim@lifesciadvisors.com
(212) 915-2564

ADVAXIS
IMMUNOTHERAPIES™

Source: Advaxis, Inc.